1. Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy
   Annamaria Ruzzo et al, 2006, JCO CrossRef
2. Polymorphisms in XRCC1, XRCC3, and CCND1 and Survival After Treatment for Metastatic Breast Cancer
   Mary A. Bewick et al, 2006, JCO CrossRef
3. Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy
   Annamaria Ruzzo et al, 2007, JCO CrossRef
4. ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy
   Stephanie Smith et al, 2007, JCO CrossRef
5. Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin.
   Devika Rao et al, 2019, Oncotarget CrossRef
6. Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis
   Dianke Yu et al, 2008 CrossRef
7. Prospective Assessment of XPD Lys751Gln and XRCC1 Arg399Gln Single Nucleotide Polymorphisms in Lung Cancer
   Daniela F. Giachino et al, 2007 CrossRef
8. Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
   Adriana Handra-Luca et al, 2007 CrossRef
9. Establishment and characterization of an oxaliplatin-resistant hepatic cancer cell line
   Ping Qiu et al, 2018 CrossRef
10. Low-dose radiation enhances susceptibility to cisplatin in resistant ovarian cancer cells via downregulation of ERCC1 and Bcl-2
    Xiaoran Liu et al, 2016 CrossRef